Managing Toxicities Associated With CAR T-Cell Therapy

Expert slides on biologic principles, indications, and clinical biomarkers for immune checkpoint inhibitors, from Clinical Care Options (CCO)

Sandip P. Patel, MD Released: April 16, 2021

Expert slides on multidisciplinary management of immune-related adverse events associated with checkpoint inhibitors, from Clinical Care Options (CCO)

Marianne Davies, DNP, CNS, ACNP-BC, AOCNP Released: April 16, 2021

Clinical Care Options (CCO) on-demand video featuring expert perspectives on using cytokine therapy for melanoma

Ahmad Tarhini, MD, PhD
Program Director George Ebanks, RN, BSN, OCN Jennifer Swank, PharmD, BCOP Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: April 8, 2021 Expired: April 7, 2022

The Current Treatment Landscape in Advanced Melanoma (12 mins)

BRAF/MEK Inhibitors and High-Dose IL-2 in Melanoma: Adverse Event Management (30 mins)

Emerging Strategies for Resistant or Progressive Disease (12 mins)

Quickly access expert treatment recommendations for patients with advanced head and neck cancer with this decision tool.

Barbara Burtness, MD
Program Director Robert L. Ferris, MD, PhD Ranee Mehra, MD Cristina P. Rodriguez, MD Jared Weiss, MD Released: April 6, 2021